NCT04165317 2026-01-22
CREST
Pfizer
Phase 3 Active not recruiting
Clinical Trials
20 trialsNCT05037279 2025-02-20
EVER
Verity Pharmaceuticals Inc.
Phase 3 Recruiting
NCT01697306 2025-01-30
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
Phase 2 Completed
NCT04806178 2024-12-09
IMMUNOBCG
University of Campinas, Brazil
Phase 3 Completed
NCT00352079 2023-08-04
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
Canadian Cancer Trials Group
Phase 3 Terminated
NCT02948543 2023-06-18
BCG+MM
University of Sydney
Phase 3 Unknown
NCT00070070 2022-10-12
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT02792192 2021-10-28
Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants
Hoffmann-La Roche
Phase 1/2 Terminated
NCT00694915 2021-08-17
STCC
Cadila Pharnmaceuticals
Phase 2 Completed
NCT02010203 2020-02-17
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
Heat Biologics
Phase 1/2 Terminated
NCT01373294 2019-08-06
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00974818 2015-11-20
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 3 Terminated
NCT01498172 2015-02-04
BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
University of Lausanne Hospitals
Phase 1 Completed
NCT01284205 2014-08-29
First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC
Bioniche Life Sciences Inc.
Phase 3 Withdrawn
NCT00002990 2013-06-12
Surgery and BCG in Treating Patients With Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00004122 2013-02-01
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT00003759 2013-01-31
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00023842 2012-09-24
BCG With or Without Mitomycin in Treating Patients With Bladder Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT01442519 2011-09-28
BCG/EMDA-MMC
University of Rome Tor Vergata
Phase 3 Completed
NCT00330707 2011-03-04
Combined Use of BCG and Interferon Alpha in Bladder Cancer
National University Hospital, Singapore
Phase 2/3 Completed